The process of drug discovery is extremely complex and requires time and resources to isolate the molecules capable of identifying the properties of a disease or virus. Health institutions are becoming increasingly dependent on the ability of computational drug discovery (CDD) to speed up and automate factors such as analytics and large-scale simulations for the trial process. To efficiently do this, drug developers are leveraging emerging technologies such as artificial intelligence and machine learning.
It has been a long wait for the pharmaceutical industry to find a technology that not only increases the effectiveness of the drug discovery and development process, but also addresses the traditional challenges of time and cost. Organisations embracing CDD are placing big bets on the technology while they adjust their vision for the future.
Across all sectors, AI has been one of the technologies at the forefront of recent digital-transformation initiatives...